Related Experiment Videos
BMS-204352 (Bristol Myers Squibb).
1Neurocrine Biosciences Inc, Department of Neuroscience, San Diego, CA 92121-1102, USA. kmackay@neurocrine.com
Current Opinion in Investigational Drugs (London, England : 2000)
|September 27, 2001
Summary
BMS-204352, a novel potassium channel opener, is being developed as a neuroprotectant for acute ischemic stroke. Clinical trials progressed rapidly through Phase III, indicating potential for market entry and significant sales.
Area of Science:
- Neuroscience
- Pharmacology
- Cardiovascular Research
Background:
- BMS-204352 is a fluoro-oxindole compound.
- It functions as a potassium channel opener.
- Bristol-Myers Squibb is developing it as a neuroprotective agent.
Purpose of the Study:
- To evaluate BMS-204352 for the treatment of acute ischemic stroke.
Main Methods:
- The drug advanced through multiple phases of clinical trials.
- Phase I trials began in Japan in 1998.
- Phase II trials commenced in the US and Japan by 1999-2000.
- Worldwide Phase III trials were initiated by March 2000.
Main Results:
- BMS-204352 progressed to worldwide Phase III clinical trials for acute stroke.
- Financial analysts projected significant market potential.
- Sales forecasts estimated $111 million by 2005 and $500 million by 2008 in the US.
Conclusions:
- BMS-204352 demonstrated progression through late-stage clinical development for stroke treatment.
- The drug showed considerable commercial potential based on analyst predictions.